Kornimate/medical-research-clean huggingface dataset:
lactate monitoring in traumatic long bone fractures requiring emergent surgical intervention

Conditions: Lactate Blood Increase; Trauma Blunt; Trauma, Secondary; Injury Traumatic

Summary: serum lactate has been utilized as a standard in guiding management of orthopedic injuries. elevated preoperative lactate has been associated with a higher likelihood of postoperative complications. however, lactate's role in guiding operative timing in non-critical long-bone fractures has not been previously explored. this study investigates lactate's role in guiding surgical timing and predicting complications secondary to delayed definitive correction in non-critical long-bone fractures with injury severity score \<16.

trauma is among the leading causes of death, disability, and hospitalizations each year worldwide. the majority of traumatic injuries are orthopedic in nature, making up nearly one million hospital encounters each year. according to the center for disease control and prevention, fractures are among the top 20 first-line diagnosis presenting to the emergency department. in recent years, the epidemiology of long bone fractures has been changing, with an increased incidence of fragility fractures in the elderly and high energy injuries affecting young adults. fall-related fractures account for 61% of emergency orthopedic surgical procedures. management of these orthopedic fractures is complex, and certain predictors such as lactate have been suggested to play a role in outcomes. in the setting of trauma, the metabolic response of insufficient tissue perfusion is anaerobic glycolysis, with serum lactate as the final byproduct. serum lactate serves as a circulating biomarker for organ oxygen supply and demand mismatch and is often used as a surrogate for tissue hypoxia. normal blood lactate levels range from 0.5 to 2.2 mmol/l, with some variability in the upper limitation. studies show early lactate clearance may be an important and independent prognostic variable in guiding management protocol for the resuscitation of trauma patients. furthermore, several studies have presented more evidence that lactate levels can be considered a sensitive marker for patients in shock and during resuscitation with strong correlation with morbidity and mortality levels. the goal of this study is to further investigate the role of serum lactate levels in guiding surgical timing and complications resulting from delay to the definitive surgical intervention in noncritical, traumatic patients with sustained long bone fractures.

Eligibility criteria:
inclusion criteria: * all patients aged 18 years or higher with long bone fractures with injury severity score \<16 exclusion criteria: * non-long bone fracture surgeries performed within the first 72 hours * patients who underwent external fixation prior to surgery * patients with inconsistent or incomplete chart data patients with polytrauma and life-threatening injuries.
tens to alleviate the effect of thirty after surgery xerostomia (dry mouth) after surgery

Conditions: Postoperative Complications

Summary: dry mouth of postoperative makes the patient feel thirst, and the pain of the lips is cracked. it will also make the sputum thick and sticky, making it difficult for the patient to cough by himself. especially the elderly may have sputum accumulation and pneumonia. dry mouth can easily change the ph value in the mouth, destroy the environment in the mouth, and increase the chance of oral mucosal lesions, ulcers and infections. the physical discomfort can lead to psychological effects such as anxiety, irritability, and irritability. the incidence of dry mouth was 88%, 6-8 hours after abdominal surgery. although the incidence is high, compared with other complications after surgery (such as: pain, bleeding, etc.), dry mouth after surgery is less important, and is underestimated, unmeasured, unrecorded and untreated. initiating the motivation of this study, it is hoped that through research to understand the relevant factors causing dry mouth after surgery, and using transcutaneous electrical nerve stimulation (tens) to improve the symptoms of dry mouth after surgery. the first phase is to describe the relevant studies with the aim of understanding the relevant factors that contribute to dry mouth after surgery. this study will understand and pay attention to the post-operative dry mouth. it is hoped that through this study, the problem of dry mouth after surgery will be improved, and the comfort of the recovery period after surgery will be improved, so that patients can get better care and promote the quality of care.

introduction a postoperative thirst is one of the major complaints in the recovery room. the purpose of this experimental study was to compare the efficiency of reducing postoperative thirst by transcutaneous electrical nerve stimulation (tens) and routine care. methods surgical patients under general anesthesia were recruited from a medical center. each patient was randomly assigned to the experimental group (tens) or control group (routine care). experimental group had 53 patients and control group had 52 patients fitted in the inclusion and exclusion criteria and completed data collection. the intensity of thirst was measured pretreatment, immediately after treatment and 30 minutes after treatment. all data were managed by spss for windows (version 21.0). descriptive and inferential statistics (chi-square test, t-test, generalized estimating equation regression analysis) were performed to identify the relationships that were proposed.

Eligibility criteria:
inclusion criteria: * anesthesiology (asa) physical status i-ιii, elective abdominal surgery, \>20 years old exclusion criteria: * pregnancy, epilepsy, unconscious

Keywords: postoperative thirty, postoperative recovery room, complain
amyotrophic lateral sclerosis web based patient care database: alsconnection.org

Conditions: Amyotrophic Lateral Sclerosis

Summary: the purpose is to collect data for als research. the data will be used to learn more about the origin of als and to improve quality of care for people with als. the information you provide in the als registry will be used to evaluate variations in patient care, adherence to standards of care and also to help foster als research.

any person who has been diagnosed with als by a physician can enroll into this registry. the information you provide in the als registry will be used to evaluate variations in patient care, adherence to standards of care and also to help foster als research. an additional focus of this website will be to educate participating patients and visitors to this site about ongoing als research.

Eligibility criteria:
inclusion criteria: * there are no inclusion and exclusion criteria beyond the fact that a person needs to have als in order to enroll.

Keywords: amyotrophic lateral sclerosis
the safety and efficacy of long-term treatment of pins stimulator system for tourette syndrome

Conditions: Tourette Syndrome

Summary: the purpose of this clinical study is to verify the long term effectiveness and safety of a bilateral deep brain stimulation (dbs) produced by beijing pins medical co., ltd. as a treatment option for patients with cognitive, behavioral, and functional disability of tourette syndrome.


Eligibility criteria:
inclusion criteria: 1. subject is aged 18 or older 2. patient group with tourette's syndrome, diagnosis of tourette syndrome by dsm-iv exclusion criteria: 1. major depressive episode within the previous 6 months 2. schizophrenia or other psychotic disorder.participate in other clinical trial; 3. has a life expectancy of \< 1 year. 4. the investigator and/or enrollment review committee, would preclude participation in the study.
compassionate use of omegaven

Conditions: Cholestasis

Summary: this expanded access protocol is for infants or children with conditions preventing them from taking in enough nutrients from food and must receive nutrition intravenously. standard intravenous nutrition contains fat emulsion made from soybean. if this fat emulsion is given over a long period of time, it can cause problems within the liver and if persistent and not addressed can even lead to severe and/or permanent injury to the liver. it is believed that a type of fish oil blend, called omegaven®, may be used in place of the soybean fat blend. the omegaven® fish oil blend may greatly reduce the risk of liver injury. omegaven® is not approved by the food and drug administration (fda). it is only offered under an "expanded access" protocol as an alternative to the soybean fat blend.


Eligibility criteria:
inclusion criteria: 1. male or female 2. older than 14 days and less than 5 years of age 3. direct bilirubin value is greater than 2 mg/dl 4. be expected to require intravenous nutrition for at least an additional 28 days 5. parent/legal guardian has agreed to provide consent/parental permission exclusion criteria: 1. patients who have a congenitally lethal condition (e.g. trisomy 13). 2. patients who have clinically severe bleeding not able to be managed with routine measures. 3. patients who have evidence of a viral hepatitis or primary liver disease as the primary etiology of their cholestasis. 4. patients who have other health problems such that survival is extremely unlikely even if the infant's cholestasis improves. 5 the parent/legal guardian is unwilling to provide consent/parental permission.
compound to control presbyopia symptoms

Conditions: Presbyopia

Summary: low dose compose to control presbyopia symptoms

a los dose compound including pilocarpine, brimonidine and oxymetazoline was use to control presbyopia symptoms compared to pilocarpine and brimonidine in low doses.

Eligibility criteria:
inclusion criteria: * healthy * presbyopic * 40 - 59 years exclusion criteria: * diabetics * previous eye surgery * previous eye disease * \> 0.50 myopia * \> 1.5 hyperopia or astigmatism
conventional versus modified pre-surgical naso-alveolar molding treatment in cleft lip and palate infants

Conditions: Cleft Lip and/or Palate; Cleft Lip Bilateral

Summary: the aim of this study is to evaluate and compare clinically conventional pre-surgical naso-alveolar molding (pnam) treatment versus modified naso-alveolar molding protocol (mpnam) in cleft lip and palate patients in terms of: 1. decreasing cleft gap. 2. attaining columellar length. 3. effect on maxillary growth. 4. treatment duration. 5. parents acceptance.


Eligibility criteria:
inclusion criteria: 1. the age range from 14 -30 days after birth. 2. has complete cleft lip and palate. 3. parents acceptance. 4. medically free infants. exclusion criteria: 1. syndromic patients. 2. medically compromised patients contradicting operation.

Keywords: cleft palate cleft lip and/or palate nasoalveolar molding
a multicenter study to evaluate the rox arteriovenous coupler in patients with treatment-resistant hypertension

Conditions: Hypertension

Summary: the purpose of this study is to evaluate the safety and performance of the rox coupler in patients with treatment-resistant hypertension.


Eligibility criteria:
inclusion criteria: * diagnosis of treatment-resistant hypertension must be made on the basis of current findings, medical history, and physical examination exclusion criteria: * any serious medical condition that may adversely affect the patient's safety, limit the subject's ability to participate in the study, comply with follow-up requirements or impact the scientific integrity of the study.

Keywords: high blood pressure hypertension resistant hypertension
phase i clinical trial to evaluate the safety, tolerability and pharmacokinetic characteristics of hsk39004 dry powder inhalation

Conditions: Healthy Volunteers

Summary: to evaluate the safety, tolerability and pharmacokinetic characteristics of hsk39004 dry powder inhalation in healthy subjects.


Eligibility criteria:
inclusion criteria: 1. voluntarily sign the informed consent form, understand the trialprocedures, and be willing to comply with all trial procedures andrestrictions; 2. 18 years to 45 years (inclusive), male and female; 3. male subjects weight ≥50 kg and female subjects weight ≥45 kg. body mass index (bmi) : 18-26 kg/m2 (inclusive) ; 4. normal lung function during the screening period, no airway obstruction, fev1 and forced vital capacity(fvc) are at least 80% of the predicted values; 5. never smoked or have quit smoking for ≥ 12 months and have a previous smoking history of \< 5 pack per years; 6. subjects are willing to voluntarily use effectivecontraceptives from screening to at least 3 months after the last dose administration. exclusion criteria: 1. have a history of severe and uncontrolled diseases, such ascardiovascular, respiratory, liver, gastrointestinal, endocrine,hematologic, mental/nervous systems diseases within 3 months prior to screening; 2. have a history of any malignant tumors; 3. normal or abnormal vital signs, physical examination, laboratory examination, electrocardiogram, and imageological examination have no clinical significance; 4. previous or current gastrointestinal, liver, kidney, or other disease known to interfere with drug absorption, distribution, metabolism, or excretion; 5. acute respiratory infections occurred within 6 weeks before screening and/or before randomization; 6. have a history of high consumption of grapefruit juice, methylxanthinerich food or beverage within 48 hours before the administration; 7. average alcohol intake is more than 14 unit per week (1unit=10g alcohol , 1 unit=285 ml 4.9% alcohol beer, or 30 ml 40% alcohol spirit, or 100ml 12% alcohol wine) within the 3 months prior to screening; 8. have a history of drug abuse prior to screening, or positive urine drug screen at screening; 9. blood donation (or blood loss) ≥400 ml within 3 months prior to the screening; 10. subjects who have a allergic to any component of hsk39004 or allergic history; 11. subjects who use any live vaccine within 30 days prior to screening; 12. have participated in any clinical investigator within 3 months prior to screening; 13. a pregnant/lactating woman, or has a positive pregnancy test at screening or during the trial; 14. not suitable for this study as judged by the investigator.
the natural history of chronic pancreatitis

Conditions: Chronic Pancreatitis; Complication; Risk Factors

Summary: chronic pancreatitis (cp) is a disease characterized by inflammation and their replacement by fibrotic tissue. the destruction of pancreatic function and structure are the main complications. this retrospective-prospective, multicenter, cohort study was conducted. this study aimed to observe the natural history of cp in china, analyse the risk factors for cp complications, and establish individual predictions.

in order to track changes consistently throughout the course of cp and facilitate the evaluation and study of cp, a dedicated database, cp database (version number 2.1, yinma information technology inc., shanghai, china), was established to collect clinical data of cp patients who were admitted to our centers. data befor cp database established were retrospectively collected according to the electronic medical record system and complemented through telephone, letter, and e-mail inquiries. data were prospectively collected since cp database was established. the following information was documented in detail: demographic data (age, sex, birthplace, et al), course of cp, medical history, history of other diseases, smoking and alcohol history, family history of pancreatic diseases and diabetes mellitus (dm), laboratory and imaging findings, and treatment strategy.

Eligibility criteria:
inclusion criteria: * patients diagnosed with chronic pancreatitis according to asia-pacific consensus exclusion criteria: * pancreatic cancer diagnosed within 2 years after the diagnosis of chronic pancreatitis * groove pancreatitis * autoimmune pancreatitis
diode laser application with non-surgical periodontal treatment

Conditions: Periodontitis

Summary: periodontitis is an infectious disease that causes destruction of periodontal tissues with complex etiology that develops due to local and systemic factors. host-derived enzymes, cytokines and proinflammatory markers are the main elements that play a role in this degradation. new techniques such as non-surgical or surgical methods combined with laser application are used for its treatment. the subjects were divided into two groups as "individuals applied with diode laser in addition to non-surgical periodontal treatment" (laser group) and "individuals with non-surgical periodontal treatment (srp)" (control group). while only non-surgical periodontal treatment was applied to individuals in the control group; in the laser group, diode laser was applied in addition to this treatment. all individuals were examined 1 and 3 months after treatment.the scaling root planing (srp) procedure was performed mechanically with gracey curettes under local anesthesia. the diode laser applied to the study group was applied parallel to the gingival sulcus at 0.80w power, 940 nm wavelength and 0.80 j / s energy level in continuous phase. gingival crevicular fluid (gcf) samples were taken without any procedure in order not to change the amount and content. all clinical parameters were also measured by the same investigator before srp and in all participants. after this treatment, the participants were re-examined in the 1st and 3rd months for control purposes and gcf samples were taken from the same regions again and the clinical parameters were measured again by the same researcher. gcf samples were stored at -20 degrees celsius until elisa studies were performed. clinical parameters (pocket depth, clinical attachment loss, bleeding on probing, gingival index, plaque index) and gingival crevicular fluid (gcf) sampling were obtained at each control. il-1β, il-10, il-17, opg, rankl, tweak, sclerostin levels in gcf samples were measured with elisa method. the aim of this study is to evaluate the effectiveness of diode laser application in addition to non-surgical treatment in periodontitis treatment clinically and biochemically and to assess the potential biomarkers for use.


Eligibility criteria:
inclusion criteria: 1. presence of 5mm or more periodontal pockets on one or more surfaces in periodontal tissues, 2. not having periodontal treatment in the last 3 months, 3. the informed consent form must be approved, 4. at least 18 years old. exclusion criteria: 1. presence of systemic disease, 2. smoking, 3. regular use of non-steroidal anti inflammatory drugs, 4. having been treated with antibiotics in the last 3 months, 5. individuals in need of pre-treatment antibiotic prophylaxis, 6. pregnancy and lactation, 7. not approving the informed consent form, 8. patients with known allergies.

Keywords: periodontitis gingival crevicular fluid diode laser sclerostin tweak
prospective trial of rituximab for primary pulmonary alveolar proteinosis

Conditions: Pulmonary Alveolar Proteinosis; Primary Disease

Summary: the purpose of this study is to determine whether the use of rituximab is effective in treating pulmonary alveolar proteinosis by leading to an improvement in lung function and disease status.

the goal of this study is to conduct a prospective, open-label 6-month trial of rituximab in patients who present with symptomatic primary or idiopathic pap. a total of 10 subjects with primary pap will be enrolled over 12 months at east carolina university. patients over age 18 with a clinical diagnosis of moderate symptomatic idiopathic pap, established by appropriate clinical history, radiographic and physiologic findings, presence of circulating anti-gm-csf antibody, and confirmatory findings on bronchoscopy with bronchoalveolar lavage and/or open-lung biopsy will be recruited. patients with newly diagnosed pap or established disease may be considered for this study.

Eligibility criteria:
inclusion criteria: * diagnosis of primary pap (new or chronic) with presence of anti-gm-csf antibody * moderately symptomatic disease with pao2 \<70 on room air and on less than 6 l/min oxygen * able to give written informed consent and comply with the requirements of the study * adequate renal and liver function * negative serum pregnancy test (for women of child bearing age) and on acceptable birth control during and after study completion exclusion criteria: * severe pap and requires in-patient care and more urgent therapy with bilateral whole lung lavage * treatment with any investigational agent within 4 weeks of screening * history of severe allergic or anaphylactic reactions to humanized or murine monoclonal antibodies * history of hiv, recurrent significant infection or recurrent bacterial infections * known active bacterial, viral, fungal, mycobacterial, or other infection * ongoing use of high dose steroids (\>10mg/day) or unstable steroid dose * significant cardiac or pulmonary disease or blood disorder

Keywords: pulmonary alveolar proteinosis primary pulmonary alveolar proteinosis rituximab idiopathic symptomatic gm-csf antibody
study of chronic degenerative diseases

Conditions: Metabolic Syndrome X

Summary: the prevalence of obesity and type 2 diabetes mellitus (dm) in children have been increasing in parallel at an alarming rate. in particular, the increasing prevalence of type 2 dm is attributable to genetic factors, clinical (waist circumference, adiposity and physical condition) and biochemical (insulin secretion and sensitivity, lipids and inflammation) risk, each of which represents an independent risk. as has already studied and published in the investigators' group, the child population of toluca has greater expression of cardiovascular risk factors than their counterparts in bogota, colombia. the metabolic characterization of the young population of toluca and bogota with new biomarkers such as homocysteine and leptin is an activity that aims to provide more metabolic data affecting young people. hypothesis: after six months of follow-up there will be a greater relative risk in mexican population to have identified another component of metabolic syndrome compared to the young population of colombia.

objective: to compare the expression levels of cardiovascular risk markers in young people between 5 and 12 years of toluca, mexico and bogota, colombia. material and methods: type of study: prospective, descriptive, comparative, and longitudinal. sample calculation: for a cohort study and taking into account that in the investigators' previous publication in the colombian population only 13% (sick rate in unexposed group) had an altered metabolic parameter; accepting an alpha risk of 0.05 and a beta of 0.2 on a risk bilateral contrast, 57 subjects were required in the exposed group (mexican population) and 57 in unexposed to detect a minimum relative risk of 3 to find other alteration to metabolic syndrome after six months follow-up. measurements: the international physical activity questionnaire (ipaq) will be applied to all children. dietary history of three days and physical examination (height in cm , weight in kg and waist circumference in centimeters) and blood pressure (mmhg) data will be recorded. blood samples will be taken to analyze glucose, cholesterol, hdl, triglycerides, homocysteine and leptin. statistics: variables will be tested for normality through the kolmogorov-smirnov and shapiro-wilk formulas. variables related to the physiological and metabolic functions and anthropometric measurements will be reported in mean and standard deviation. the differences in the laboratorial and anthropometrical variables will be analyzed with the student t test. a difference will be considered significant with a p value ≤ 0.05. the statistical program used is the statistical package for the social sciences (spss) version 19.

Eligibility criteria:
inclusion criteria: * primary school students of medium-low income. exclusion criteria: * children with disabilities or a known chronic disease.

Keywords: hyperlipidemias hyperglycemia hypertension leptin hyperhomocysteinemia